Literature DB >> 31867080

Intramastoid Phosphaturic Mesenchymal Tumor Causing Hypophosphatemic Osteomalacia Detected on 68Ga-DOTATATE PET/CT But Not on 99mTc-Sestamibi and 18F-FDG Scans.

Carlo Scognamiglio Renner Araujo1, Luciana Parente Costa Seguro1, Paulo Schiavom Duarte2,3, Carlos Alberto Buchpiguel2, Rosa Maria Rodrigues Pereira1.   

Abstract

68Ga-DOTATATE uptake in mesenchymal tumors causing hypophosphatemic osteomalacia has been recently described. Herein, we present a case of 68Ga-DOTATATE uptake in an intramastoid phosphaturic mesenchymal tumor that had not been depicted in previous 99mTc-Sestamibi and 18F-FDG scans. The lesion was surgically removed and the phosphorus level increased to the normal range. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  DOTA; Gallium-68; Hypophosphatemic; Mastoid; Osteomalacia; PET/CT

Year:  2019        PMID： 31867080      PMCID： PMC6898704          DOI： 10.1007/s13139-019-00616-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  12 in total

1.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

2.  Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia.

Authors:  B D Nguyen; E A Wang
Journal:  Clin Nucl Med       Date:  1999-02       Impact factor: 7.794

3.  Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy.

Authors:  Y Rhee; J D Lee; K H Shin; H C Lee; K B Huh; S K Lim
Journal:  Clin Endocrinol (Oxf)       Date:  2001-04       Impact factor: 3.478

4.  Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.

Authors:  J C Reubi; B Waser; J A Laissue; J O Gebbers
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

5.  Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.

Authors:  Roderick J Clifton-Bligh; Michael S Hofman; Emma Duncan; Ie-Wen Sim; David Darnell; Adele Clarkson; Tricia Wong; John P Walsh; Anthony J Gill; Peter R Ebeling; Rodney J Hicks
Journal:  J Clin Endocrinol Metab       Date:  2013-01-07       Impact factor: 5.958

6.  Neoplastic pathology of oncogenic osteomalacia/rickets.

Authors:  N Weidner; R S Bar; D Weiss; M P Strottmann
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

7.  Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.

Authors:  Kanhaiyalal Agrawal; Sanjay Bhadada; Bhagwant Rai Mittal; Jaya Shukla; Ashwani Sood; Anish Bhattacharya; Anil Bhansali
Journal:  Clin Nucl Med       Date:  2015-01       Impact factor: 7.794

8.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

9.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Authors:  Michelle Houang; Adele Clarkson; Loretta Sioson; Marianne S Elston; Roderick J Clifton-Bligh; Michael Dray; Dominique Ranchere-Vince; Anne-Valerie Decouvelaere; Arnaud de la Fouchardiere; Anthony J Gill
Journal:  Hum Pathol       Date:  2013-09-20       Impact factor: 3.466

10.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394
View more
  1 in total

Review 1.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.